Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
about
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolismDirect thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillationOral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolismOral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosisDirect thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with non-valvular atrial fibrillationPharmacist-managed clinics for patient education and counseling in Japan: current status and future perspectivesPharmacology of argatroban.Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot TrialCosts and clinical consequences of suboptimal atrial fibrillation management.Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjectsDabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.Use of Continuous Renal Replacement Therapy for Removal of Dabigatran in a Patient in Need of Emergent Surgery.The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency.Case report: dabigatran-associated gynecologic bleeding.Dabigatran etexilate: future directions in anticoagulant treatment.Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation.Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease.A retrospective assessment comparing pharmacist-managed anticoagulation clinic with physician management using international normalized ratio stability.The role of apixaban for venous and arterial thromboembolic disease.Dabigatran or rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety.The pharmacology and therapeutic use of dabigatran etexilate.Anticoagulants: A Review of the Pharmacology, Dosing, and Complications.New anticoagulants and antiplatelet agents: a primer for the clinical gastroenterologist.Efficacy and safety of novel anticoagulants compared with established agents.Bilateral subconjunctival hemorrhage secondary to abciximab use: case report.Thrombin Receptor Agonist Peptide-Induced Platelet Aggregation Is Reduced in Patients Receiving Dabigatran.Direct Thrombin Inhibitors
P2860
Q24187205-07D4C1FD-1B35-4865-AFAA-9A2A0FC18BC2Q24197843-C379F3F7-AAB7-42F8-9934-56F9878026D3Q24200864-B8A6652B-0EE4-4BA6-9DA1-AB4AE542D18BQ24200867-915731C7-78A4-4759-9861-91B652F8B133Q24202488-9D017AD3-86C3-4494-9E5E-293E8D341BD1Q26773091-FEAC4668-D054-4918-83AF-BDB3FBA04866Q33392860-6CC46744-CE1D-4D54-8656-6D2A55804B72Q33698353-3499053E-3F10-4631-ABB3-47CDB355F481Q35885128-F8C5E9E4-5523-47C2-88CD-75337F51D28EQ36729949-32BAE017-93DE-4FDC-91C7-F46BF0D9DA2DQ36841028-ACA1A711-5A5D-428D-A502-50DAABFD367AQ36985504-6C763633-C5EE-48B5-B0A0-5B19185ED4F9Q37063974-96C29C18-B0CB-4EF2-B3D9-CB5EC1B428BEQ37340101-BC8845CC-6084-4857-A47C-F5227A5F8516Q37579455-889A2119-1E74-4E91-A8D5-85C364C364B0Q37832237-6FFC485B-EA15-45FF-93CE-48BEDA27E869Q37870757-F5718F57-EE01-498C-945F-27F99B673FAAQ37871725-72C85DD4-BDD0-4616-96FB-582769AD600CQ37895164-B7E0C964-B83D-49BE-AE8D-F402B4641E7EQ37939851-70B11895-8665-4440-92E3-10085E15769AQ38043448-7D3B25DC-D74B-427A-A836-CC871D36BA53Q38080765-ED11BA1E-F840-4E69-AA01-0BED34DBB90FQ38107945-A556A907-192D-4228-83E3-055B16CAC57FQ38176801-34369A58-E1B7-41F2-BBE4-1E64B19C421AQ42017822-8796E504-7101-4479-869D-585AB6205194Q50135555-2AF2FDD1-C48E-4D62-9284-1CB40ED92261Q50531533-81055209-26B1-41B5-B916-D6D5E0E43E2FQ56003308-DFD7A786-3DFA-435B-980E-CC578A3C0E05
P2860
Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Dabigatran etexilate: an oral ...... nt of thromboembolic diseases.
@ast
Dabigatran etexilate: an oral ...... nt of thromboembolic diseases.
@en
type
label
Dabigatran etexilate: an oral ...... nt of thromboembolic diseases.
@ast
Dabigatran etexilate: an oral ...... nt of thromboembolic diseases.
@en
prefLabel
Dabigatran etexilate: an oral ...... nt of thromboembolic diseases.
@ast
Dabigatran etexilate: an oral ...... nt of thromboembolic diseases.
@en
P2860
P356
P1433
P1476
Dabigatran etexilate: an oral ...... nt of thromboembolic diseases.
@en
P2093
Brooke E Baetz
Sarah A Spinler
P2860
P304
P356
10.1592/PHCO.28.11.1354
P407
P577
2008-11-01T00:00:00Z